Hypotonic cerebral palsy: mapping what is known and what is missing

Hypotonic cerebral palsy is a less studied subtype, with low muscle tone and large differences in how people respond to rehabilitation. Our work so far is evidence mapping. It proposes research questions. It does not report patient data and it does not claim a cure or a treatment.

What we did

A preprint scoping review, published on Zenodo on 9 May 2026, searched PubMed/MEDLINE and Semantic Scholar for biomarkers that may predict rehabilitation response in hypotonic cerebral palsy, and summarised the findings narratively.

What it found

Evidence that directly addresses hypotonic cerebral palsy is sparse. Related literature on broader CP groups points to a few candidates: MRI connectivity measures, EEG coherence, the BDNF Val66Met variant and serum BDNF. The review found no prospective study that has validated a biomarker panel to predict rehabilitation response in this group, and it proposes future cohort studies.

A later revision (version 3, on NEUVORA Labs) focuses on dopamine-related polygenic scores and BDNF/TrkB biology, and lists eight research questions. Related work in other CP groups, for example the 2017 eBioMedicine and 2025 PLOS One studies on dopamine gene scores, suggests the question is worth testing in hypotonic CP.

Limits

• Not peer-reviewed.
• Single author, so selection of studies and interpretation can be biased.
• Much of the evidence is indirect: spastic CP, brain injury or preclinical work.
• No pooled estimate and no formal risk-of-bias assessment.

Read it

• Preprint on Zenodo (9 May 2026), DOI 10.5281/zenodo.20092430
• Revised version 3 and the eight research questions, NEUVORA Labs

No charts here: the review reports no quantitative data, so there is nothing to plot. We will not add a chart for the sake of it.